Adamas Pharma (ADMS) Reports Q1 Loss of $1.06/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2018
March 4, 2019 4:35 PM ESTEMERYVILLE, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported recent achievements and financial results for the fourth quarter and full-year ended December 31, 2018, along with key priorities for 2019.Â
We are excited to expand GOCOVRIs impact on Parkinsons patients with dyskinesia in 2019, after finishing 2018, our first year of commercialization, with $34 million in sales, said Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas Pharmaceuticals, Inc. GOCOVRIs unique potential to meaningfully reduce both dyskinesia and OFF time in patients with Parkinsons disease receiving... More
